About
Investors

Leading a transformational approach to cell and gene therapies for diseases of the skin and connective tissue

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, has begun a Phase I/II trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of linear scleroderma. In addition, Fibrocell has a third program in the research phase for the treatment of arthritis and related conditions. Fibrocell’s gene-therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow us on Twitter at @Fibrocell.

Stock Quote



Recent Happenings


Our News and Events

    Press Release

October 06, 2016 9:15 a.m. PT

Cell & Gene Meeting on the Mesa 2016

View Event
    Event



E-mail Alerts

Sign up to receive e-mail alerts whenever new information posts to the Fibrocell Science site.Fibrocell Science





Forward-Looking Statements

This websites contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Fibrocell’s future operations, financial performance, financial position, prospects, strategies and objectives and other future events. In some cases, you can identify forward-looking statements by words such as “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “scheduled” and similar expressions, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based upon Fibrocell’s current expectations, intentions and assumptions regarding future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of Fibrocell’s control, that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to: risks that results seen in preclinical studies may not be replicated in humans; uncertainties relating to the initiation and completion of clinical trials and whether the results will validate and support the safety and efficacy of our product candidates; the outcome of regulatory review of Fibrocell’s product candidates; Fibrocell’s ability to obtain additional capital to complete the development and commercialization of its product candidates; Fibrocell’s ability to maintain its collaborations with Intrexon; and the other factors discussed under the caption “Item 1A. Risk Factors” in Fibrocell’s most recent annual report on Form 10-K and its most recent quarterly report on Form 10-Q, which are available through the “Investors & Media – SEC Filings” section of this website. Additionally, other unknown, unidentified or unpredictable factors could also materially and adversely impact actual results. As a result, you should not place undue reliance on forward-looking statements.

The forward-looking statements contained on this website represent Fibrocell’s views only as of "08/04/16" (or such earlier date on which it was made). While Fibrocell may update certain forward-looking statements from time to time, it specifically disclaims any obligation to do so, whether as a result of new information, future developments or otherwise.




Printer Friendly Version E-mail this page RSS E-mail Alerts Download Financial Tear Sheet